[Challenge of studies on the development of new Zn complexes to treat diabetes mellitus]

Yakugaku Zasshi. 2011;131(6):925-30. doi: 10.1248/yakushi.131.925.
[Article in Japanese]

Abstract

In recent years, people all over the world have suffered from various diseases such as cancer, myocardial infarction, osteoporosis, hypertension, and diabetes mellitus (DM). Especially, DM, well-known as one of lifestyle-related diseases, has been regarded as a serious problem, because it is difficult to fully recover. The number of patients suffering from DM in 2007 was reported to be approximately 200 million people worldwide. However, insulin preparations and synthetic therapeutics, which are clinically used treatment of DM, have been associated with problems such as physical and mental pain due to daily injections and certain severe side effects, respectively. Zn, which is an essential trace element in animals and humans and plays an important role in maintenance of their lives, has been indicated to exhibit insulin-like activity. Since the finding of insulin-like effects of Zn, several Zn complexes have been proposed as a new type of anti-diabetic therapeutics which is differ from existing medicines. In this symposium, we introduce the anti-diabetic effect, complication relieving effect, and action mechanism of bis(2-mercaptopyridine-N-oxidato)Zn complex with Zn(S(2)O(2)) coordination mode.

Publication types

  • Review

MeSH terms

  • Adiponectin / blood
  • Administration, Oral
  • Animals
  • Blood Glucose / metabolism
  • Diabetes Mellitus / drug therapy*
  • Drug Design*
  • Glycated Hemoglobin / metabolism
  • Humans
  • Hypoglycemic Agents / pharmacokinetics
  • Hypoglycemic Agents / pharmacology
  • Hypoglycemic Agents / therapeutic use*
  • Insulin / blood
  • Intestinal Absorption
  • Mice
  • Rats
  • Zinc Compounds / chemistry
  • Zinc Compounds / pharmacokinetics
  • Zinc Compounds / pharmacology
  • Zinc Compounds / therapeutic use*

Substances

  • Adiponectin
  • Blood Glucose
  • Glycated Hemoglobin A
  • Hypoglycemic Agents
  • Insulin
  • Zinc Compounds
  • hemoglobin A1c protein, human